CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today the closing of its public offering of 4,700,000 shares of common stock. Net proceeds to the company are approximately $101 million. The offering was underwritten by Banc of America Securities LLC.
